SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Edgewise Reports FDA Meeting and Submits EDG-7500 Phase 3 Protocol

Edgewise Therapeutics says it submitted the STRATUS-HCM Phase 3 protocol after an end-of-Phase 2 meeting with the FDA. The protocol features tolerability-based dose escalation without safety echo monitoring.

EWTX

Related stories